Nectar Lifesciences PE ratio history and valuation
NSE: NECLIFEBSE: 532649Pharmaceuticals & BiotechnologySmall Cap
Nectar Lifesciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2005
Last close ₹10.53up ₹0.07 (0.67%)BSE ₹10.60
Share price at the NSE close on 27 Oct 2026. Previous close ₹10.46.
27 Oct: open ₹10.46, high ₹10.66, low ₹10.26
52-week range of traded prices to 27 Oct 2026
₹9.30Low, 30 Mar 2026₹22.40High, 23 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 27 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹205 Cr2,221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −31.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹171 crore of one-off items, the largest of them in the quarter to Sep 2025.
- −9.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −15.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,24,40671.9% delivered
Nectar Lifesciences' price to book, price to sales, dividend yield and earnings yield on 27 Oct 2026, each against its own history of up to 10 years. It has no P/E: its profit over the twelve months to Jun 2026 is a loss. The ratios use standalone accounts to Mar 2020 and consolidated from Mar 2021.
Nectar Lifesciences PE ratio and valuation against its own history
- Price to earningsLoss, last twelve months
- Price to book0.35today
3 years
Median 0.61Today is at or above 10% of the 659 days
5 years
Median 0.51Today is at or above 8% of the 1,155 days
10 years, since Nov 2018
Median 0.45Today is at or above 20% of the 1,881 days
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.40.82today
1 year
Median 0.38Today is at or above 86% of the 247 days
3 years
Median 0.42Today is at or above 95% of the 740 days
5 years
Median 0.37Today is at or above 97% of the 1,236 days
10 years
Median 0.33Today is at or above 99% of the 2,475 days
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.Operating loss, last twelve months
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.00%today
1 year
Median 0.00%Today is at or above 100% of the 247 days
3 years
Median 0.00%Today is at or above 100% of the 743 days
5 years
Median 0.00%Today is at or above 100% of the 1,239 days
10 years
Median 0.00%Today is at or above 51% of the 2,478 days
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.−119.80%today
1 year
Median −127.99%Today is at or above 60% of the 247 days
3 years
Median −0.37%Today is at or above 20% of the 740 days
5 years
Median −4.18%Today is at or above 12% of the 1,236 days
10 years
Median 1.19%Today is at or above 6% of the 2,475 days
Each track ranks every trading day in the window from the day the ratio was lowest to the day it was highest; the dot is today. The share under it is how many of those days the ratio was at or below today's level, so a high share means today is higher than on most days in the window. A window is shown only when the ratio is held on most of its trading days; a day after a loss-making year has no P/E. Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
- Price to book =Market cap÷Net worthNet worth. Shareholders' equity in the latest balance sheet. Net worth in the glossary₹582 Cr
- Price to sales =Market cap÷Revenue, last twelve monthsRevenue, last twelve months. Revenue from operations over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹5.01 Cr
- Enterprise value =Market cap+BorrowingsBorrowings. Total borrowings in the latest balance sheet. Borrowings in the glossary₹0.00 Cr−CashCash. Cash and bank balances in the latest balance sheet.₹112 Cr
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.19,42,60,970at 30 Sep 2026
- Net profit, last twelve monthsNet profit, last twelve months. Net profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).
- −₹245 Cr
- Operating profit, last twelve monthsOperating profit, last twelve months. Profit before depreciation, interest and tax over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).
- −₹89 Cr
Consolidated accounts, the twelve months to Jun 2026, balance sheet at Mar 2026, ₹ crore.Nectar Lifesciences financials ›
Nectar Lifesciences valuation at each year end
On the last trading day of each March, the month the company's year ends.Nectar Lifesciences dividend history
| Ratio | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market cap (₹ crore)Market capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. | 787 | 589 | 387 | 220 | 417 | 539 | 358 | 676 | 515 | 181 |
| Price to earnings | 14.7 | 10.4 | 11.4 | 5.3 | Loss | Loss | Loss | 83.7 | 30.3 | Loss |
| Price to book | No balance sheet | No balance sheet | 0.4 | 0.2 | 0.4 | 0.5 | 0.3 | 0.6 | 0.5 | Shares changed |
| Price to sales | 0.5 | 0.3 | 0.1 | 0.1 | 0.2 | 0.3 | 0.2 | 0.4 | 0.3 | 0.3 |
| EV to EBITDA | No balance sheet | No balance sheet | 5.1 | 4.1 | 8.7 | 9.5 | 13.3 | 10.9 | 6.4 | Operating loss |
| Dividend yield | 0.28% | 0.19% | 0.29% | 0.51% | 0.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings yield | 6.8% | 9.7% | 8.7% | 19.0% | −6.0% | −5.1% | −4.5% | 1.2% | 3.3% | −196.5% |
A ratio that does not exist on the day says why in its cell. The ratios are on standalone accounts to Mar 2020 and consolidated from Mar 2021.
Nectar Lifesciences market cap, ten years
The last trading day of each month.
Market cap, ₹ crore
- Market cap
Earnings per share, book value and enterprise value
From the close on 27 Oct 2026, with the last twelve months' results.
- Enterprise valueEnterprise value. Market cap plus borrowings less cash and bank balances: what it would cost to buy the whole business, its debts included.
- ₹92 Cr
- Earnings per shareEarnings per share, trailing. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) divided by the number of shares in issue.
- −₹12.61
- Book value per shareBook value per share. Net worth, the company's assets less everything it owes, divided by the number of shares in issue.
- ₹29.97
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- None
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹99 Cr
Against Pharmaceuticals
216 listed companies in Pharmaceuticals, each priced on its last trading day; Nectar Lifesciences is 125th among them by market cap. Each median leaves out Nectar Lifesciences itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 28.4Across 159 other companies
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 3.0Across 190 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 19.9Across 147 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.50%Across 89 other companies
| Company | |||||
|---|---|---|---|---|---|
 Gennex LaboratoriesGENNEX | 216 | 11.74 | 0.97 | 9.3 | 0.00% |
 Sat Kartar LifeSATKARTAR | 212 | 11.11 | 2.43 | – | 0.52% |
 Accretion PharmaceuticalsACCPL | 206 | 21.27 | 3.76 | – | 0.00% |
 Sanjivani ParanteralSANJIVIN | 205 | – | 4.24 | 14.7 | 0.00% |
| Nectar LifesciencesNECLIFE | 205 | – | 0.35 | – | 0.00% |
 Accretion NutravedaANL | 197 | 38.83 | 5.55 | – | 0.00% |
 Kerala AyurvedaKERALAYUR | 196 | – | – | – | 0.00% |
| Bio Medica LaboratoriesBMLL | 195 | 16.69 | – | – | 0.00% |
 Syschem (India)SYSCHEM | 192 | – | 1.38 | 9.3 | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.